A critical appraisal of safety data on dydrogesterone for the support of early pregnancy: a scoping review and meta-analysis

Katalinic, Alexander; Shulman, L.P.; Strauss, Jerome F.; García-Velasco, Juan A.; Anker, John N. van den

doi:10.1016/j.rbmo.2022.03.032

Cited by 24 publications

(18 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In multiparous women or women whose education level was less than university degrees, the duration of progesterone treatment was less than 12 weeks, and these results were adjusted by regression. This relationship has also been stated in other studies that a lower literacy level and higher parity are related to an increase in the incidence of PTB 26 …”

Section: Discussionsupporting

confidence: 82%

“…This relationship has also been stated in other studies that a lower literacy level and higher parity are related to an increase in the incidence of PTB. 26 So far, studies have not reported long-term effects on fetuses of women who received progesterone in the first trimester. 27 In the same direction as the studies included in a review, Coomarasamy et al 22 showed no statistical difference in congenital anomalies between the progesterone group and the placebo group.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association between the duration of progesterone supplementation treatment and premature neonates outcomes: A retrospective cohort study

Kazemi Aski,

Sharami,

KabodMehri

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background and AimsPreterm birth (PTB) is the leading cause of perinatal mortality and morbidity, progesterone is one of the main hormones to maintain a normal pregnancy. However, there are still conflicting results regarding using progesterone supplementation to prevent PTB and improve neonatal outcomes. The length of treatment with progesterone supplementation is also one of the challenges ahead, so the present study was conducted to investigate the relationship between the duration of progesterone supplementation treatment and neonatal outcomes.MethodsThis retrospective cohort study was conducted on pregnant women at risk of PTB and who have taken progesterone supplementation. They were asked about the length of treatment with progesterone supplements and finally, the neonatal outcomes of these women were measured.ResultsA total of 265 pregnant women who met the inclusion criteria were included in this study and the subjects were divided into two groups that received progesterone <12 weeks and received progesterone ≥12. In the group of women receiving progesterone with a treatment duration of ≥12 weeks, the rate of preterm labor, respiratory distress syndrome, low birth weight, and the need for hospitalization were significantly lower than in the group receiving progesterone with a treatment duration of ≥12 weeks.ConclusionProgesterone administration for longer than 12 weeks in women at risk of PTB can improve neonatal outcomes.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Association between the duration of progesterone supplementation treatment and premature neonates outcomes: A retrospective cohort study

Kazemi Aski,

Sharami,

KabodMehri

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…Evaluation of the long‐term effects of progesterone treatment during pregnancy, especially during the first trimester, is extremely difficult primarily due to confounding factors and loss to follow‐up. To date, no studies have reported any long‐term outcomes according to progesterone or progestogens given in the first trimester 31 . Of the studies included in the present review, Coomarasamy et al 13 showed no statistical difference in congenital anomalies between the progesterone group and the placebo group.…”

Section: Progesterone Supplementation In Generalmentioning

confidence: 70%

“…Of the studies included in the present review, Coomarasamy et al 13 showed no statistical difference in congenital anomalies between the progesterone group and the placebo group. Furthermore, to date, no evidence supports or suggests that dydrogesterone, used in the study included in this review (El‐Zibdeh 14 ), is associated with a risk of fetal congenital anomalies 31 …”

Section: Progesterone Supplementation In Generalmentioning

confidence: 96%

“…To the best of our knowledge, no publications have specifically studied the effect of progesterone on safety in patients with recurrent miscarriage; however, evidence of its safety in other areas including reproductive medicine, reproductive endocrinology, and infertility is well documented where progesterone is considered innocuous. This is based on a wealth of experience and its use in a large number of patients over the years 31 …”

Section: Progesterone Supplementation In Generalmentioning

confidence: 99%

See 1 more Smart Citation